Cityscape: 1L Tiragolumab + Atezolizumab Vs Placebo + Atezolizumab In Pd-L1-Selected Nsclc

CITYSCAPE: 1L tiragolumab + atezolizumab vs placebo + atezolizumab in PD-L1-selected NSCLC

CITYSCAPE: tiragolumab in NSCLC

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

EMJ

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

Dr Chitresh Aggarwal | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a 1L

CRSF - Cancer Research and Statistic Foundation

Dr Melissa Johnson: Tiragolumab Plus Atezolizumab Improves Objective Response in CITYSCAPE Trial

NSCLC highlights at ASCO 2020

Final OS results of IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma

The Emergence of PD-L1 Inhibitors

Atezolizumab Versus Other Immunotherapy Options

ASCO Lung Cancer Roundtable - NSCLC - The CITYSCAPE Trial: Anti TIGIT & Immune Checkpoint Inhibitor

GRACE - Global Resource for Advancing Cancer Education

BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC

What role does TIGIT inhibition have in treating hepatocellular carcinoma?

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

PARCT: atezolizumab for CTCL and next steps

VJHemOnc – Video Journal of Hematology & HemOnc

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091

Highlights in early non-metastatic NSCLC and thoracic tumours